Basic HTML Version
127
SCIENTIFIC REPORT 2012
Title:
Multicenter, randomized, single-blind, parallel-group study to evaluate
The short- and long-term efficacy of certolizumab pegol plus methotrexate compared with
adalimumab and methotrexate in subjects with moderate to severe rheumatoid arthritis
inadequate to methotrexate.
District Attorney:
UCB-PHARMA.
Principal Investigator:
Antoni Gómez Centeno.
Title:
Four-year follow-up extension study to evaluate efficacy, safety and
Long-term tolerability of secukinumab in patients with active rheumatoid arthritis.
District Attorney:
Novartis Farmacéutica SA
Principal Investigator:
Antoni Gómez Centeno.
Title:
Efficacy, pharmacokinetics and safety of BI 695500 versus rituximab in patients with
moderate or intensely active rheumatoid arthritis: randomized, double-blind,
parallel groups and multiple doses of comparison with active product.
District Attorney:
Berhringer-Ingelheim Pharmaceuticals.
Principal Investigator:
Antoni Gómez Centeno.
Title:
Randomized, double-blind, parallel, placebo-controlled study to evaluate the
efficacy and safety of the addition of sarilumab to treatment with antirheumatic drugs
Non-biological disease modifiers (DMARDs) in patients with rheumatoid arthritis
whose response to TNF-antagonists is insufficient or they do not tolerate these drugs.
District Attorney:
Sanofi-Aventis SA
Principal Investigator:
Antoni Gómez Centeno.
Title:
Immunogenicity of Anti TNF Therapies in Patients with Diseases
Rheumatism. REASON study.
District Attorney:
Pfizer, SLU
Principal Investigator:
Antoni Gómez Centeno.
Title:
ALIGN-Transversal study, multinational to determine specific beliefs and
Patients' general information regarding medication and treatment compliance
selected systemic diseases for chronic inflammatory diseases (EIMI).
District Attorney:
ABBOTT LABORATORIES SA
Principal Investigator:
Antoni Gómez Centeno.